Welcome to our dedicated page for Quantum-Si Incorporated SEC filings (Ticker: QSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for Quantum-Si Incorporated (Nasdaq: QSI), a proteomics technology and life sciences company focused on single-molecule protein analysis and Next-Generation Protein Sequencing. Here, investors can review how Quantum-Si reports its financial performance, capital structure, and material corporate events in official regulatory documents.
Quantum-Si’s periodic reports, such as its quarterly results furnished via Form 8-K, provide detail on product and service revenue, cost of revenue, research and development spending, selling, general and administrative expenses, and items like lease termination or legal settlement expenses. These filings also include condensed consolidated balance sheets and statements of operations, along with non-GAAP metrics such as adjusted total operating expenses and adjusted EBITDA, together with reconciliations to GAAP measures.
Capital markets and financing activities are documented in Forms 8-K and related registration statements. Examples include a registered direct offering of Class A common stock and pre-funded warrants, an at-the-market Sales Agreement for Class A common stock, and the termination of a prior equity distribution agreement. Filings describe intended uses of proceeds, such as funding the Proteus platform development, commercialization, manufacturing development, research and development, and general corporate purposes.
Other material agreements and corporate actions, including lease terminations, settlement and mutual release agreements, and inducement equity awards under the 2023 Inducement Equity Incentive Plan, are also reported in Quantum-Si’s SEC filings. Stock Titan’s interface adds AI-powered summaries that highlight key terms, financial impacts, and timelines from these documents, helping readers quickly understand complex agreements, capital raises, and operating decisions without reading every line of each filing.
Quantum-Si Inc reported that Chief Financial Officer Jeffry R. Keyes received new equity awards. He was granted stock options for 780,847 shares of Class A common stock at an exercise price of
Keyes was also granted 652,803 restricted stock units, increasing his direct common stock holdings to 1,816,000 shares after the grant. The RSUs vest in four equal annual installments beginning on
Quantum-Si Inc Chief Product Officer John S. Vieceli received new equity awards. On
He also received 391,681 restricted stock units, each representing one share of common stock upon vesting, on the same vesting schedule starting
Quantum-Si Inc President & CEO Jeffrey Alan Hawkins reported equity compensation awards rather than open-market trades. He received a stock option covering 1,561,695 shares of Class A common stock at an exercise price of
Quantum-Si Inc reported that its General Counsel and Corporate Secretary, Christian LaPointe, received new equity awards. He was granted 261,121 shares of Class A common stock in the form of restricted stock units and a stock option for 312,339 shares at an exercise price of
Quantum-Si Inc director Charles R. Kummeth reported an open-market purchase of 500,000 shares of Class A common stock on March 5, 2026. The weighted average purchase price was $0.9196 per share, with individual trades executed between $0.8906 and $0.9735 per share. Following this transaction, he directly holds 855,000 shares of Quantum-Si common stock.
Quantum-Si Inc director Paula Dowdy purchased Class A common stock in an open-market transaction. On March 5, 2026, she bought 109,890 shares at a weighted average price of $0.9505 per share, and held 269,107 shares directly after the trade.
The footnote explains that the $0.9505 figure is a weighted average, with actual purchase prices ranging from $0.9051 to $0.9730 per share. Detailed price breakdowns are available upon request from regulators, the company, or its security holders.
Quantum-Si Incorporated is an early-stage life sciences technology company focused on proteomics, aiming to make single-molecule protein sequencing widely accessible. It has developed its Platinum and higher-priced Platinum Pro next-generation protein sequencing instruments, sold with proprietary library preparation and sequencing kits plus Platinum Analysis Software.
The company targets research-use-only applications today, positioning its platform as a lower-cost, automated alternative and complement to legacy mass spectrometry and affinity-based methods. Management describes a large addressable market within a broader proteomics opportunity and plans to drive recurring consumables revenue from a growing installed base. A major roadmap milestone is the Proteus platform, expected to launch by the end of 2026 with much higher feature density and automation. Key risks include continued net losses and funding needs, potential delays or underperformance of Proteus, dependence on single-source contract manufacturers and semiconductor processes, evolving data, privacy and healthcare regulations, and governance factors such as controlled-company status, dual-class stock and the need to maintain Nasdaq listing.
Quantum-Si Incorporated reported wider full-year losses while preparing for its next-generation Proteus platform launch. For 2025, revenue was $2.4 million, with gross profit of $1.2 million and a gross margin of 47%. The company posted a 2025 net loss of $101.3 million, similar to the prior year, but reduced adjusted operating expenses to $86.3 million from $99.0 million.
In the fourth quarter of 2025, revenue was $0.5 million with a 27% gross margin and a net loss of $17.6 million. Management highlighted significant cost discipline and one-time litigation charges of $18.7 million during 2025. As of December 31, 2025, cash, cash equivalents and marketable securities totaled $215.8 million, which the company believes funds operations into the second quarter of 2028.
For 2026, Quantum-Si issued guidance for revenue of approximately $1.0 million, adjusted total operating expenses of $98.0 million or less, and total cash usage of $93.0 million or less. The company expects 2026 to be a transition year, intentionally moderating revenue as it embeds upgrade credits and placement programs to support a stronger commercial launch of the Proteus system, which has a list price of $425,000 and is targeted for launch by the end of 2026.
Quantum-Si Inc director Amir Jafri received a grant of 114,055 stock options on Class A Common Stock at an exercise price of $0.00 per share. The options vest in equal monthly installments beginning on March 31, 2026, subject to continued service. Following this, he directly holds 115,942 Class A shares.
Quantum-Si Incorporated (QSI) filed a Form 8-K to furnish materials from its Investor & Analyst Day held on November 19, 2025. The company used this event to present slides and a webcast replay that provide updates and summaries of its business, which are available in the Investors section of its website and attached as Exhibit 99.1. The company states that the information in this report, including Exhibit 99.1, is being furnished rather than filed under the Exchange Act and is not deemed incorporated into other securities filings unless specifically referenced.